Display options
Cite
El Helou G, Ponzio TA, Goodman JF, et al. Tetravalent dengue DNA vaccine is not immunogenic when delivered by retrograde infusion into salivary glands. Trop Dis Travel Med Vaccines. 2020;6:10doi: 10.1186/s40794-020-00111-5.
El Helou, G., Ponzio, T. A., Goodman, J. F., Blevins, M., Caudell, D. L., Raviprakash, K. S., Ewing, D., Williams, M., Porter, K. R., & Sanders, J. W. (2020). Tetravalent dengue DNA vaccine is not immunogenic when delivered by retrograde infusion into salivary glands. Tropical diseases, travel medicine and vaccines, 610. https://doi.org/10.1186/s40794-020-00111-5
El Helou, Guy, et al. "Tetravalent dengue DNA vaccine is not immunogenic when delivered by retrograde infusion into salivary glands." Tropical diseases, travel medicine and vaccines vol. 6 (2020): 10. doi: https://doi.org/10.1186/s40794-020-00111-5
El Helou G, Ponzio TA, Goodman JF, Blevins M, Caudell DL, Raviprakash KS, Ewing D, Williams M, Porter KR, Sanders JW. Tetravalent dengue DNA vaccine is not immunogenic when delivered by retrograde infusion into salivary glands. Trop Dis Travel Med Vaccines. 2020 Jun 03;6:10. doi: 10.1186/s40794-020-00111-5. eCollection 2020. PMID: 32518668; PMCID: PMC7268334.
Copy Download .nbib Format: NLM
Share it on

Trop Dis Travel Med Vaccines. 2020 Jun 03;6:10. doi: 10.1186/s40794-020-00111-5. eCollection 2020.

Tetravalent dengue DNA vaccine is not immunogenic when delivered by retrograde infusion into salivary glands.

Tropical diseases, travel medicine and vaccines

Guy El Helou, Todd A Ponzio, Joseph F Goodman, Maria Blevins, David L Caudell, Kanakatte S Raviprakash, Daniel Ewing, Maya Williams, Kevin R Porter, John W Sanders

Affiliations

  1. Department of Medicine, Division of Infectious Diseases and Global Medicine, University of Florida, Gainesville, FL USA.
  2. Department of Medicine, Division of Infectious Diseases, Wake Forest School of Medicine, Winston-Salem, NC USA.
  3. Department of Otolaryngology, George Washington School of Medicine and Health Sciences, Washington, DC 20037 USA.
  4. Department of Pathology, Section on Comparative Medicine, Wake Forest School of Medicine, Winston-Salem, NC USA.
  5. Naval Medical Research Center, Silver Spring, MD USA.

PMID: 32518668 PMCID: PMC7268334 DOI: 10.1186/s40794-020-00111-5

Abstract

INTRODUCTION AND BACKGROUND: A tetravalent DNA vaccine for Dengue virus is under development but has not yet achieved optimal immunogenicity. Salivary glands vaccination has been reported efficacious in rodents and dogs. We report on a pilot study testing the salivary gland as a platform for a Dengue DNA vaccine in a non-human primate model.

MATERIALS AND METHODS: Four cynomolgus macaques were used in this study. Each macaque was pre-medicated with atropine and sedated with ketamine. Stensen's duct papilla was cannulated with a P10 polyethylene tube, linked to a 500ul syringe. On the first two infusions, all macaques were infused with 300ul of TVDV mixed with 2 mg of zinc. For the 3rd infusion, to increase transfection into salivary tissue, two animals received 100uL TVDV mixed with 400uL polyethylenimine 1μg/ml (PEI) and the other two animals received 500uL TVDV with zinc. Antibody titers were assessed 4 weeks following the second and third infusion.

RESULTS AND CONCLUSIONS: SGRI through Stensen's duct is a well-tolerated, simple and easy to reproduce procedure. TVDV infused into macaques salivary glands elicited a significantly weaker antibody response than with different delivery methods.

© The Author(s) 2020.

Keywords: DNA vaccine; Non-human primate; Salivary gland infusion; Tetravalent dengue vaccine

Conflict of interest statement

Competing interestsN/A

References

  1. Mol Ther. 2003 Sep;8(3):392-9 - PubMed
  2. Curr Opin Infect Dis. 2011 Oct;24(5):442-50 - PubMed
  3. Hum Gene Ther. 2007 Feb;18(2):142-50 - PubMed
  4. Trop Dis Travel Med Vaccines. 2017 Feb 17;3:4 - PubMed
  5. Hum Mol Genet. 1992 Sep;1(6):363-9 - PubMed
  6. Proc Natl Acad Sci U S A. 2012 Nov 20;109(47):19403-7 - PubMed
  7. N Engl J Med. 2018 Jul 26;379(4):327-340 - PubMed
  8. Oral Dis. 2002 Nov;8(6):275-81 - PubMed
  9. Cancer Gene Ther. 1999 Nov-Dec;6(6):505-13 - PubMed
  10. Vaccine. 2019 Jul 26;37(32):4444-4453 - PubMed
  11. Am J Trop Med Hyg. 2018 Mar;98(3):849-856 - PubMed
  12. Methods Mol Biol. 2014;1143:283-95 - PubMed
  13. Gene Ther. 2010 Nov;17(11):1318-24 - PubMed
  14. Eur J Oral Sci. 2002 Jun;110(3):254-60 - PubMed
  15. Gene Ther. 2015 Sep;22(9):739-49 - PubMed
  16. J Cell Physiol. 1998 Nov;177(2):264-73 - PubMed
  17. Vaccine. 2004 Jun 23;22(19):2500-4 - PubMed
  18. Hum Gene Ther. 2008 Dec;19(12):1401-5 - PubMed
  19. Expert Opin Biol Ther. 2015;15(10):1443-54 - PubMed
  20. Science. 1993 Mar 19;259(5102):1745-9 - PubMed

Publication Types